[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-neuropathy":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,50,77,97,130,160,188,216,240,264,293,324,349,378,418,440,470,493,517,543,581,610,632,662,692],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644360","phase-2-sacituzumab-tirumotecan-vs-mmae-adcs-in-advanced-urothelial-carcinoma-fuscc-spare-uc-01-100644360",false,"NCT07662863","Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)","A Randomized, Open-label, Phase II Study Evaluating the Neurotoxicity and Efficacy of Sacituzumab Tirumotecan (Sac-TMT) Versus MMAE-based ADCs in Patients With Advanced Urothelial Carcinoma: The SPARE-UC-01 Trial","SPARE-UC-01","Inclusion Criteria\n\n1. Must voluntarily sign the written Institutional Review Board (IRB)\u002FEthics Committee (EC) approved informed consent form (ICF) prior to any screening procedures.\n2. Age \\> 18 years at the time of signing the ICF.\n3. Histologically or cytologically confirmed locally advanced (unresectable) or metastatic urothelial carcinoma (UC), including bladder, ureter, renal pelvis, or urethra. Participants with mixed histology are eligible provided that UC is the predominant component (\\> 50%).\n4. Must have received at least one prior line of systemic therapy for locally advanced or metastatic UC (e.g., Enfortumab Vedotin plus Pembrolizumab, Disitamab Vedotin plus Toripalimab, platinum-based chemotherapy, immune checkpoint inhibitors, Nectin-4 ADCs, HER2 ADCs, FGFR inhibitors, or other palliative chemotherapy regimens).\n5. Neuropathy Status:\n\n   Cohort A\u002FB: Baseline peripheral neuropathy (PN) Grade 0-1 (per NCI-CTCAE v5.0) with stable nerve function confirmed by Nerve Conduction Study (NCS) during screening.\n\n   Cohort C (Observational): Baseline PN Grade 2, or a history of PN \\> Grade 2 where the investigator deems the patient unsuitable for MMAE-based ADC treatment.\n6. At least one measurable lesion per RECIST v1.1. (Lesions in previously irradiated areas are considered target lesions only if clear progression is documented after radiotherapy).\n7. ECOG Performance Status of 0 or 1 at screening.\n8. Expected survival \\> 3 months.\n9. Must have adequate organ and bone marrow function (no blood transfusion, growth factors, or albumin support within 14 days prior to screening):\n\n   * Hematological: ANC \\>= 1.5 x 10\\^9\u002FL; Platelets \\>= 75 x 10\\^9\u002FL; Hemoglobin \\>= 90 g\u002FL.\n   * Hepatic: ALT and AST \\\u003C= 2.5 x ULN (or \\\u003C= 5 x ULN for patients with liver metastases); Total Bilirubin \\\u003C= 1.5 x ULN (if Total Bilirubin \\> 1.5 x ULN, Direct Bilirubin must be \\\u003C= ULN).\n   * Coagulation: INR \\\u003C= 1.5; APTT \\\u003C= 1.5 x ULN; PT \\\u003C ULN + 4 seconds.\n   * Renal: Creatinine Clearance (CrCl) \\>= 30 mL\u002Fmin, or Serum Creatinine \\\u003C= 1.5 x ULN.\n\nExclusion Criteria\n\n1. Prior treatment with TROP2-targeted ADCs, topoisomerase I inhibitors (e.g., irinotecan, topotecan), or ADCs containing topoisomerase I inhibitor payloads.\n2. Patients previously treated with both Enfortumab Vedotin (EV) and Disitamab Vedotin (DV) are excluded from Cohorts A and B (eligible for Cohort C only).\n3. Treatment with any investigational anti-tumor agents, chemotherapy, immunotherapy, monoclonal antibodies, targeted therapy, or radical radiotherapy within 2 weeks or 5 half-lives (whichever is shorter) prior to the first dose. Major surgery within 4 weeks prior to the first dose.\n4. Active CNS or meningeal metastases. Patients with previously treated CNS metastases are eligible if clinically stable for ≥ 4 weeks, off systemic corticosteroids for ≥ 2 weeks (physiological replacement ≤ 10 mg\u002Fday prednisone equivalent is allowed), and no evidence of radiographic progression.\n5. History of non-infectious pneumonitis\u002Finterstitial lung disease (ILD) requiring steroids. Current ILD or suspected ILD on screening chest CT (even if asymptomatic). Severe COPD, severely impaired lung function, or requirement for long-term oxygen therapy.\n6. QTcF interval \\> 470 ms (females) or \\> 450 ms (males). Within 6 months prior to the first dose: myocardial infarction, unstable angina, severe arrhythmia requiring intervention, uncontrolled hypertension, stroke, or TIA. NYHA Class III or IV congestive heart failure.\n7. Active keratitis, corneal ulcer, or severe dry eye syndrome.\n8. Active Hepatitis B (HBsAg positive and HBV-DNA \\> 2000 IU\u002FmL; patients with lower HBV-DNA must receive antiviral therapy); Active Hepatitis C (HCV antibody and RNA positive); Known HIV infection; Severe infection requiring IV antibiotics within 2 weeks prior to first dose.\n9. Hypersensitivity: Known severe hypersensitivity to sac-TMT, EV, DV, or their excipients.\n10. Any severe or uncontrolled systemic disease that, in the investigator's opinion, increases the risk to the participant.\n11. HbA1c ≥ 8% (Patients with well-controlled blood glucose, fasting glucose ≤ 10 mmol\u002FL, and investigator approval are eligible).\n12. History of allogeneic stem cell transplant or solid organ transplant.\n13. Pregnant or breastfeeding females.","ALL","18 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The main goal of this clinical trial is to learn if a new targeted cancer drug called sacituzumab tirumotecan (sac-TMT) works to treat cancer while causing less nerve damage in patients with advanced urothelial carcinoma who have progressed on or could not tolerate previous treatment such as enfortumab vedotin plus pembrolizumab (EVP) or disitamab vedotin plus toripalimab (DVT).\n\nThe main question it aims to answer is: Does sac-TMT lower the risk of getting severe nerve damage, as measured together by doctors, machines, and the participants?\n\nResearchers will compare sac-TMT to alternative MMAE-based ADC drugs (switching to a different MMAE-based ADC after the first one stopped working) to see if sac-TMT causes less nerve damage while still effectively treating the cancer. A small group of participants who had to stop their previous MMAE-based ADC treatment because of nerve damage will also receive sac-TMT to learn if the drug is safe for their nerves.\n\nParticipants will:\n\n1. Receive either sac-TMT or another MMAE-based ADC drug\n2. Have regular physical exams by a doctor to check their nerves\n3. Have machine tests to measure how well their nerves work\n4. Answer survey questions about their pain, numbness, and daily activities",[28,29,30,31],"Bladder Cancer","Metastatic Urothelial Carcinoma","Urothelial Carcinoma","Peripheral Neuropathy",[31,33,34,35,36],"Sacituzumab Tirumotecan","Enfortumab Vedotin","MMAE","Disitamab Vedotin","NOT_YET_RECRUITING","2026-06-17",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":43,"type":22},"2026-07-15",{"date":45,"type":22},"2029-12-01",{"name":47,"class":48},"Fudan University","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100644315","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-early-stage-cancer-100644315","NCT07663396","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of early-stage cancer(I-III stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. Non small cell lung cancer or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal; Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with advanced cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":58,"type":22},278,[60],"NA","This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with early stage cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[63,64,31,65],"Electroacupuncture","Chemotherapy","Early Stage Cancer",[67,64,68,69],"electroacupuncture","Peripheral neuropathy","early stage cancer",{"date":40,"type":41},{"date":72,"type":22},"2026-05-25",{"date":74,"type":22},"2029-07-31",{"name":76,"class":48},"Affiliated Hospital of Qinghai University",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":96,"locationsCount":49},"100642496","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-advanced-cancer-100642496","NCT07644533","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of advanced cancer(IV stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer;\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. NSCLC or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with early-stage cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":85,"type":22},264,[60],"This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with advanced cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[63,64,89,31],"Advanced Cancer",[64,89,68,63],"2026-06-10",{"date":93,"type":41},"2026-06-12",{"date":72,"type":22},{"date":74,"type":22},{"name":76,"class":48},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100643683","prospective-case-series-evaluating-6-month-and-12-month-outcomes-after-cryoneurolysis-for-chronic-pain-100643683","NCT07639060","Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain","Inclusion Criteria:\n\n* Diagnosis of chronic pain (generally pain duration of at least 3-6 months) localized to an anatomical region appropriate for cryoneurolysis as determined by the treating physician.\n* Planned cryoneurolysis procedure as part of standard clinical care.\n* Ability to provide written informed consent.\n* Ability and willingness to complete baseline and follow-up questionnaires.\n\nExclusion Criteria:\n\n* Cryoneurolysis performed as part of a separate investigational trial in which data sharing is not permitted.\n* Active infection or other clinical contraindication to the procedure as determined by the treating clinician.\n* Life expectancy of less than 12 months in the judgment of the treating clinician.\n* Any condition that, in the investigator's opinion, would interfere with study participation or completion of follow-up, such as severe psychiatric instability or active substance use that precludes reliable follow-up",{"count":104,"type":22},80,"OBSERVATIONAL","To prospectively describe patient-centered and health utilization outcomes through 12 months after cryoneurolysis performed as routine clinical care for chronic pain at Yale.",[108,109,110,111,112,113,114,115,116,117,118,119,120,121],"Chronic Pain","PERIPHERAL NEUROPATHY","Occipital Neuralgia","Chronic Hip Pain","Hip Osteoarthritis","Knee Osteoarthritis","Spasticity","Chronic Low Back Pain","Lumbar Spondylosis","Cervical Spondylosis","Shoulder Arthritis","Causalgia","Chronic Pain Syndrome","Chronic Neck Pain","2026-06-05",{"date":91,"type":41},{"date":125,"type":22},"2026-06",{"date":127,"type":22},"2028-07",{"name":129,"class":48},"Yale University",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":49},"100512300","wiredup-wearable-insoles-for-recurrent-diabetic-ulcer-prevention-100512300","NCT05950659","WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention","Prevention of Foot Ulcer Recurrence in Individuals Who Are at High-risk for Diabetic Foot Complications Using the Orpyx Sensory Insole System: a Multisite, Randomized, Controlled Trial","WIREDUP","Inclusion Criteria:\n\n* Diagnosed Type 1 or 2 diabetes\n* Clinically diagnosed neuropathy via Neuropathy Monofilament Test (Appendix A)\n* Qualification as a \"high-risk participant,\" meaning a recent history (\\\u003C12 months) of a healed diabetic neuropathic ulceration on the weight-bearing surface of one or both feet (this includes the plantar distal toe surface)\n* Complete healing of any previous foot ulcers, as defined by complete re-epithelialization of that ulcer which is confirmed by two medical exams that occur at least two weeks apart (screening visit and baseline study visit)\n* Ability to walk independently (without use of wheelchair) for 30 steps. Use of a walker or cane is acceptable as long as the participant can walk for at least 30 steps.\n* Aged \\>18 years\n* ABI \\> 0.6 or TBI \\> 0.4 or palpable pulses or evidence of healing in the last 2 months. If ABI \\\u003C 0.4, the patient's vascular lab studies (ABI, TBI, pulse volume recordings) will be reviewed by the study PI and a co-I vascular surgeon at USC.\n* Subject is willing and able to maintain the required offloading (as applicable for the location of the healed ulcer)\n* Subject is willing and able to wear the Orpyx Sensory Insoles during ambulatory activity and at home during waking hours, and for a minimum of 5 hours per day\n* Amputations, if present, are compatible with the use of insoles at physician discretion (e.g. Transmetatarsal Amputation (TMA) are acceptable)\n\nExclusion Criteria:\n\n* Active ulcer or presence of other open chronic wound (on foot or leg), regardless of etiology (e.g., vasculitis, neoplasms, or hematological disorders)\n* Dementia\n* Psychiatric illness or social situations that would limit compliance with the study\n* Significant cardiopulmonary, severe imbalance, or other systemic disease limiting the participant's ability to walk at least 30 steps or to stand for an amount of time equal to or greater than five (5) minutes (self-reported)\n* Current participation in another clinical investigation of a similar medical device designed to offload or prevent diabetic foot ulcer formation; or participation in such a study within 30 days prior to study enrollment, per physician discretion\n* Current enrollment in any other remote patient pedal monitoring (RPPM) program\n* Osteomyelitis or gangrene of the lower extremity\n* Uncorrected plantar Charcot neuroarthropathy\n* Bunion which would predispose ulcer formation (clinician discretion)\n* Extreme equinus\n* At the start of V1, and prior to randomization, the subject no longer meets the entrance criteria (inclusion and exclusion)\n* Above ankle amputation\n* Amputations not compatible with the insole, per physician discretion\n* Foot deformities or amputations that require surgical intervention as the next step in standard of care, and that the study footwear and device would not adequately address (to be adjudicated by an outside review panel).\n* Brannock-measured foot size \\> Men's 14 (Women's 12)\n* Physician discretion",{"count":139,"type":22},400,[60],"The primary aim of this study is to demonstrate the impact of the Orpyx® Sensory Insoles (Orpyx Medical Technologies Inc., Calgary AB, Canada) (\"Orpyx\" or \"the Company\") as an adjunct to the standard of care (SOC), as compared to SOC alone, on reducing plantar ulceration incidence in individuals who are at risk for developing diabetic foot complications.\n\nThe secondary aims of this study are to evaluate participant quality of life, participant engagement, and economic impact, including cost-effectiveness and cost-utility. The study will also use the unique data set collected (plantar pressure, temperature, step count, movement and adherence feedback) to identify foot-loading histories that either lead to or prevent the development of ulceration in the diabetic foot.",[143,31,144,145],"Diabetes","Diabetic Foot","Diabetic Foot Ulcer",[147,148,149],"Remote Patient Monitoring","Sensor-based Monitoring","Sensory Insoles","RECRUITING","2026-06-04",{"date":153,"type":41},"2026-06-08",{"date":155,"type":41},"2026-04-22",{"date":157,"type":22},"2029-04-01",{"name":159,"class":48},"Johns Hopkins University",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":49},"100601386","phase-2-desloratadine-to-prevent-taxane-induced-peripheral-neuropathy-in-patients-with-breast-cancer-100601386","NCT07109817","Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer","Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)","DETOXp","Inclusion Criteria:\n\n* Patients must have histologically confirmed breast cancer, stage I-III as per the American Joint Committee on Cancer (AJCC) 8th edition (Anatomic Staging)\n* Patients must be planned to receive taxane-based regimen for breast cancer (Adjuvant or neoadjuvant) of at least 12 weeks duration. Patients planned to receive taxanes in combination with other chemotherapy drugs (including platinums) are eligible. Patients planned to receive taxanes plus single or dual antiher2 therapy are also eligible. Patients planned to receive taxane-based regimen with immune checkpoint inhibitors are also allowed\n* Age ≥18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%)\n* Patients must have an adequate organ and marrow function as defined below:\n* absolute neutrophil count ≥1,000\u002Fmicroliter (mcL)\n* platelets ≥100,000\u002FmcL\n* total bilirubin ≤ institutional upper limit of normal (ULN)\n* AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN\n* Creatinine ≤ institutional ULN\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with prior diagnosis of diabetes mellitus are allowed if the patient has no peripheral neuropathy\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants\n* Patients must not have received prior taxane or platinum therapy\n* Women of childbearing potential must have a negative pregnancy test: serum or urine beta human chorionic gonadotropin (hCG) within 14 days prior to first dose of study treatment\n* Potential fertile subjects must agree to use adequate contraception (double barrier methods of birth control or abstinence) prior to start of treatment, for the duration of treatment, and 28 days after last study medication dose. If male, must also agree to refrain from donating sperm during this period\n\nExclusion Criteria:\n\n* Patients with prior diagnosis of peripheral neuropathy\n* Patients who received chemotherapy for the current breast cancer diagnosis before the planned taxane-based regimen\n* Patients who are receiving any other investigation agents\n* Patients with concurrent use of antihistamines during or for 2 days prior to the study period\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to desloratadine\n* Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous\n* Pregnant or breastfeeding women are not allowed in the study\n* Patients who are taking probiotics\n* Patients who are using chronic laxatives or enema\n* Patients who used antibiotics within 4 weeks of registration",{"count":169,"type":22},116,[25],"This is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike substance with no drug) and use validated neurotoxicity and quality of life questionnaires to determine if desloratadine can be used to prevent or make taxane induced peripheral neuropathy (TPIN) symptoms better.",[173,31],"Breast Cancer",[175,176,177,178,179],"Patient reported outcomes","Biomarkers","Taxane","Neuroinflammatory","Cytokine","2026-05-28",{"date":182,"type":41},"2026-05-29",{"date":125,"type":22},{"date":185,"type":22},"2030-09",{"name":187,"class":48},"Montefiore Medical Center",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":49},"100618804","shortwave-diathermy-in-home-treatment-for-indianapolis-va-only-patients-diagnosed-with-peripheral-artery-disease-and-peripheral-neuropathy-100618804","NCT07336381","Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy","An Exploratory Clinical Study Using the Replexa+ Device in Veterans With Lower Extremity Peripheral Artery Disease Experiencing Peripheral Neuropathy","Replexa+","Inclusion Criteria:\n\n1. Diagnosis of peripheral artery disease (PAD).\n2. Participants must exhibit PAD severity, defined by the following manifestation and corresponding Rutherford classifications:\n\n   Claudication of the index limb (Rutherford Category 2 or 3- documented as pain with walking) in conjunction with one or more of the following:\n   * ankle brachial index (ABI) greater than or equal to 0.6 mmHg, as measured no more than 6 months prior to screening\n   * resting toe brachial index (TBI) greater than or equal to 0.4, as measured no more than 6 months prior to screening\n\n   Note: In cases where ankle and toe systolic pressures are unavailable due to calcification and\u002For toe amputation, collection of angiographic data is acceptable to determine locations of blockages or reduced perfusion.\n3. Diagnosis of peripheral neuropathy, as evidenced by review of medical records.\n4. Competent to give consent.\n5. Age 18 years or older.\n\nExclusion Criteria:\n\n1. Impaired skin integrity in the location(s) to be treated.\n2. Current wounds or ulcerations.\n3. Diagnosis of active bleeding tendencies, hemorrhage, or thrombosis.\n4. 2+ pitting edema in either lower extremity.\n5. Active infection defined as elevated white blood cell count \\>11,500\u002FµL or fever \\>101.5 degrees Fahrenheit or currently taking antibiotic medication(s) for an active infection.\n6. Existence of metal hardware in the area(s) to be treated: Any patient with implanted electronic or metal device such as a pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, IUD, surgical staples or implanted metallic leads.\n7. Pregnant individuals.\n8. Presence of renal disease (creatinine \\> 2.5 mg\u002Fdl and estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin) or patients on chronic hemodialysis.\n9. History of skeletal tuberculosis.\n10. Patients, in the investigator's opinion, whose index limb condition is rapidly deteriorating and may require major amputation within 30 days of screening.\n11. Conditions that impair cognitive function.\n12. Severe concomitant disease(s), or any additional condition(s) which the investigator feels constitute(s) criteria for exclusion of a particular subject.",{"count":197,"type":22},10,[60],"This research project is designed to see if treatment with the Replexa+ shortwave diathermy device daily for 3 months will improve blood flow in the lower legs and feet of patients diagnosed with peripheral artery disease and peripheral neuropathy.",[201,31],"Peripheral Arterial Disease",[203,204,205,206,207],"peripheral artery disease","peripheral neuropathy","lower extremity artery disease","lower extremity neuropathy","PAD","2026-05-27",{"date":182,"type":41},{"date":211,"type":22},"2026-07-01",{"date":213,"type":22},"2027-12-31",{"name":215,"class":48},"Indiana University",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100470314","prevention-of-oxaliplatin-induced-nerve-damage-in-the-bodys-extremities-100470314","NCT05404230","Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities","Prevention of Oxaliplatin-induced Peripheral Neuropathy - a Randomized Controlled Trial","OxaNeuro","Inclusion Criteria:\n\n* Histopathologically verified adenocarcinoma of the colon or rectum and planned standard adjuvant treatment with capecitabine in combination with oxaliplatin.\n* ECOG performance status 0-2 (measurement of a patient's function in terms of self-care, daily activity and physical ability.\n* Written and orally informed informed consent\n\nExclusion Criteria:\n\n* Inability to speak, read, and understand Danish.\n* Previous treatment with neurotoxic chemotherapy.\n* Neurological (including neuropathy) or psychiatric disorders, diabetes or other significant medical conditions.\n* Alcohol or drug abuse.\n* Sensory disturbances in the feet\n* Spinal stenosis.\n* Vascular disease (Fontaine grade II or more).\n* Known allergy to fish, fish oil or corn oil\n* Fertile patients not willing to use effective methods of contraception during treatment or abstinence.\n* Daily intake of oil supplements and not willing to stop during the trial period.\n* Lack of consent to skin biopsy",{"count":225,"type":22},120,[60],"The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal cancer.",[31,229],"Colorectal Cancer","2026-05-18",{"date":232,"type":41},"2026-05-19",{"date":234,"type":41},"2022-07-15",{"date":236,"type":22},"2028-12",{"name":238,"class":48},"Vejle Hospital",4,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100617639","effect-of-hands-and-feet-exercises-on-taxane-based-chemotherapy-induced-peripheral-neuropathy-in-patients-with-solid-tumors-100617639","NCT07321236","Effect of Hands and Feet Exercises on Taxane Based Chemotherapy Induced Peripheral Neuropathy in Patients With Solid Tumors","Effect of Hands and Feet Exercises on Severity of Taxane-Based Chemotherapy-Induced Peripheral Neuropathy in Patients With Solid Tumors: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Cancer patients receiving taxane-based chemotherapy on alternate week.\n* Age 20-60 years, both male and female.\n* Patients having Grade I neuropathy by NCI-CTCEA criteria.\n\nExclusion criteria:\n\n* Patients with peripheral neuropathy not caused by chemotherapy.\n\n  * Patient with type-1 and type- 2 diabetes.\n* Patients with neuropsychiatric disorders.\n* Patients having any skin ulcer.\n* Individuals having hand foot fracture and varicose veins.\n* Individuals with paraplegia.\n* Patients receiving radiotherapy.","20 Years","60 Years",{"count":250,"type":22},58,[60],"The goal of this clinical trial is to determine whether hand and foot exercises can reduce the severity of Taxane-based chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients aged 20-60 years who have Grade 1I neuropathy as defined by the NCI-CTCAE criteria.\n\nThe main questions it aims to answer are:\n\n* Do hand and foot exercises reduce the severity of sensory and motor neuropathic symptoms in patients receiving Taxane based chemotherapy?\n* Is the severity of peripheral neuropathy lower in the exercise group compared to patients receiving standard care alone? Researchers will compare patients receiving standard care (control group) with those receiving standard care plus a structured hand and foot exercise program (experimental group) to see if the exercises lead to greater improvement in neuropathy severity scores.\n\nParticipants will:\n\n* Receive baseline assessment using the EORTC QLQ-CIPN20 questionnaire.\n* In the experimental group, learn and perform a 15-minute hand and foot exercise routine on chemotherapy day and continue it at home using a provided brochure.\n* Participate in telephonic follow-ups to support compliance and monitor symptoms.\n* Undergo a follow-up assessment at alternate week to measure changes in neuropathy severity.",[31],[68,177,64],"2026-04-29",{"date":257,"type":41},"2026-05-06",{"date":259,"type":22},"2026-06-01",{"date":261,"type":22},"2026-09-01",{"name":263,"class":48},"University of Health Sciences Lahore",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":49},"100635114","acupuncture-and-exercise-for-ev-pembro-induced-peripheral-neuropathy-100635114","NCT07548476","Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy","Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy (ACE)","ACE","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Diagnosed with pathologically proven advanced or metastatic urothelial cancer (mUC)\n* Planning to receive treatment with EV-Pembro or have received up to two cycles of EV-Pembro treatment with enrollment occurring prior to the start of the third cycle\n* Self-reported ability to walk for 6 minutes and\u002For 2 blocks\n* Deemed acceptable for exercise by their treating provider\n* Sedentary, currently engaging in less than or equal to 60 minutes of moderate or vigorous structured exercise\u002Fweek, as assessed by the Godin Leisure-Time Exercise Questionnaire\n* Willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments\n* Eligible per verbally administered Physical Activity Readiness Questionnaire (PAR-Q+)\n* Referrals to physical therapy are allowed during the study if necessary; and\n* Participants taking any of medications listed below must be on a stable regimen, with no changes in the past three months. Use of these medications may continue while on study.\n* Duloxetine, amitriptyline, nortriptyline, gabapentin, and pregabalin\n\nExclusion Criteria:\n\n* History of peripheral neuropathy prior to EV-Pembro initiation\n* Patients with a pacemaker or other electronically charged medical device; or\n* Participate in more than 60 minutes of moderate or vigorous structured exercise\u002Fweek\n\nInvestigators will not include the following special populations:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers \\\u003C 18 years)\n* Pregnant women\n* Prisoners",{"count":273,"type":22},50,[60],"The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro).\n\nThe names of the two study groups in this research study are:\n\n* Acupuncture + Virtual Exercise (AVE)\n* Virtual Exercise Only (VE)",[277,31,278,279],"Metastatic Bladder Cancer","Advanced Urothelial Cancer","Metastatic Urothelial Cancer",[281,282,283],"Enfortumab Vedotin-Induced Neuropathy","Pembrolizumab-Induced Neuropathy","mUC","2026-04-28",{"date":286,"type":41},"2026-05-04",{"date":288,"type":22},"2026-10-02",{"date":290,"type":22},"2027-03-02",{"name":292,"class":48},"Dana-Farber Cancer Institute",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":299,"sex":18,"minAge":19,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":303,"conditions":304,"keywords":308,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":49},"100457544","investigational-use-of-neuromuscular-ultrasound-100457544","NCT05237973","Investigational Use of Neuromuscular Ultrasound","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Healthy Volunteers-Adults\n\n   1. Healthy adults, male or female, aged 18 years old or older,\n   2. In good general health as evidenced by medical history, medical conditions under control such as hypertension acceptable.\n   3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n   4. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Participants with neuromuscular disorders\n\n   1. Adults, male or female, aged 18 years old or older,\n   2. Diagnosed with a neuromuscular disorder or have signs and symptoms of nerve or muscle disorder or neuromuscular diaphragm dysfunction.\n   3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n   4. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n1. Healthy Volunteers-Adults\n\n   History of stroke, muscle disorders, peripheral neuropathy, or spine surgery\n2. Participants with neuromuscular disorders\n\nNo clinical evidence of a neuromuscular disorder on clinical evaluation.",true,"110 Years",{"count":302,"type":22},150,"Background:\n\nCurrent techniques used to measure the health and function of a person s nerves and muscles are generally effective, but they do have limits. Researchers are looking for ways to improve the ability to observe nerves and muscles and how they function in this natural history protocol.\n\nObjective:\n\nTo study the use of ultrasound (sound waves) to learn more about nerves and muscles.\n\nEligibility:\n\nHealthy adults, aged 18 and older, with no history of stroke, nerve or muscular disorders, or spine surgery are also needed. A smaller population of adults aged 18 and older who have a neuromuscular disorder or show symptoms of nerve or muscle disorder will also be evaluated.\n\nDesign:\n\nParticipants will be screened with a medical record review.\n\nParticipants will have up to 5 outpatient clinic visits. Most participants will have 1 or 2 visits. Visits will last for less than 3-4 hours each.\n\nDuring each visit, participants will give a brief medical history and have a physical exam.\n\nParticipants will have ultrasounds to get pictures and measurements of their nerves and muscles. Gel will be applied to their skin. A probe will be placed on the skin surface. Sound waves sent through the probe will be used to create pictures.\n\nParticipants may have nerve conduction studies. Wires will be taped to the skin surface near a muscle or nerve in the arm or leg. The nerve will be stimulated with a small electric current that feels like a rubber band flick. The response will be recorded through the wires.",[305,31,306,307],"Muscular Dystrophy","Motor Neuron Disorder","Normal Physiology",[309,310,311,312,313,314],"Neuromuscular","Ultrasound","Elastography","Muscle","Nerve","Natural History","2026-04-21",{"date":155,"type":41},{"date":318,"type":41},"2022-04-18",{"date":320,"type":22},"2026-08-03",{"name":322,"class":323},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":339,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":348},"100600323","nerve-excitability-in-cisplatin-induced-peripheral-neuropathy-100600323","NCT07095998","Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy","Evaluation of Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy","Inclusion Criteria Cohort A:\n\n* Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.\n* Participants must have adequate hematologic parameters to allow chemotherapy.\n\nExclusion Criteria Cohort A:\n\n* Pre-existing peripheral neuropathy;\n* Family history of a genetic\u002Ffamilial neuropathy;\n* Any contraindication for treatment with cisplatin as determined by their primary oncologist;\n* Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;\n* Patients with cardiac or spinal stimulating devices;\n* Women who are pregnant or breastfeeding;\n* Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;\n* Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;\n* Patients not considered to be able to comply with the protocol.\n\nInclusion Criteria Cohort B:\n\n* Adults age ≥ 18 with a diagnosis of cis-PN.\n* The last dose of cisplatin must be ≥ 3 months prior to study enrollment. Patients who may have been previously enrolled in Cohort A of this study are eligible to participate in Cohort B if they continue to have cis-PN symptoms 3 months after completion of cisplatin therapy.\n\nExclusion Criteria Cohort B:\n\n* Pre-existing peripheral neuropathy;\n* Family history of a genetic\u002Ffamiliar neuropathy;\n* History of cisplatin-based regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;\n* Patients with cardiac or spinal stimulating devices;\n* Women who are pregnant or breastfeeding;\n* Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;\n* Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;\n* Patients not considered to be able to comply with the protocol.",{"count":332,"type":22},60,[60],"This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.",[336,31,337,338],"Peripheral Neuropathy Due to Chemotherapy","Neurotoxicity Syndromes","Neuropathy",[336,31,337,338],"2026-04-18",{"date":155,"type":41},{"date":343,"type":41},"2026-01-31",{"date":345,"type":22},"2028-12-31",{"name":347,"class":48},"Ka-Wai Ho",2,{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":49},"100631513","optimizing-integrative-oncology-approaches-to-address-chemotherapy-induced-peripheral-neuropathy-in-gastrointestinal-gi-cancer-patients-a-smart-pilot-study-100631513","NCT07501663","Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study","Inclusion Criteria:\n\n* Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study:\n\n  * Age 18 years or older,\n  * Self-reported moderate (≥ 2\u002F4) numbness and tingling on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Numbness and Tingling Severity Item in the previous week,\n  * At least three months since the last receipt of neurotoxic chemotherapy,\n  * Prior receipt of paclitaxel, docetaxel, cisplatin, oxaliplatin, nab-paclitaxel, or carboplatin for the treatment of stage I-III Gastrointestinal (GI) cancers,\n  * Speaking\u002Freading English.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  * Prognosis of ≤ 3 months,\n  * Documented neuropathy attributed to other causes (e.g., diabetic neuropathy),\n  * Intention to initiate a new prescription of duloxetine or other pain medications (i.e., first-line treatment for CIPN pain) during the study period; however, participants may continue on duloxetine or other pain medications if initiated at least 8 weeks before study enrollment, with no change in dose, and reporting unmanaged CIPN (i.e., ≥ 2\u002F4) PRO-CTCAE numbness\u002Ftingling severity in the last week,\n  * Currently using alcohol (ethyl), which means regular alcohol consumption (defined as ≥7 drinks\u002Fweek for women, ≥14 drinks\u002Fweek for men, or binge drinking \\>3 drinks per occasion at least weekly) within the past 3 months, or current alcohol use disorder or inability\u002Funwillingness to abstain from alcohol during the study intervention period,\n  * Currently using calcium salts, iron preparations or magnesium salts orally,\n  * With thyroid disorders, particularly those with hypo- or hyperthyroidism,\n  * With thiamine deficiency, as assessed and verified by the physician.",{"count":332,"type":22},[60],"The objective of the proposed pilot is to test the feasibility, acceptability, and preliminary efficacy of a 16-week sequential, multiple assessment randomized trial (SMART), which includes virtual Tai Chi\u002FQi Gong or α- Lipoic acid (ALA) supplements as an initial treatment, and acupuncture as the additional treatment, that examines a stepped-care intervention to address CIPN.",[31],[360,361,362,363,364,365,366,367,368],"Gastrointestinal","Peripheral Neuropathy in Gastrointestinal","Chemotherapy-induced Peripheral Neuropathy","CIPN","Tai Chi","ALA","Qi Gong","Acupuncture","SMART","2026-04-09",{"date":371,"type":41},"2026-04-14",{"date":373,"type":41},"2026-01-20",{"date":375,"type":22},"2027-04",{"name":377,"class":48},"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":385,"maxAge":248,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":390,"conditions":391,"keywords":395,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":49},"100629468","phase-2-the-effect-of-oral-dlbs1033-in-patients-with-diabetic-polyneuropathy-100629468","NCT07475065","The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy","The Effect of Oral DLBS1033 as Adjuvant Therapy on Inflammatory Biomarkers, Neuroregeneration Biomarkers, and Disease Severity in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial (An Evaluation of Changes in TCNS, TNF-α, NGF, and Sensory Nerve Conduction Study of the Sural Nerve)","Inclusion Criteria:\n\n* Adults aged 40-60 years diagnosed with diabetic polyneuropathy by a neurologist or neurology resident.\n* Patients with HbA1c levels between 7-10% within the past 30 days.\n* Willing to participate and able to sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or planning pregnancy.\n* History of other neurological diseases such as stroke, myelopathy, alcoholic neuropathy, or compressive radiculopathy.\n* Significant renal impairment (creatinine \\> 1.5× upper limit of normal), hepatic impairment (SGOT or SGPT \\> 3× upper limit of normal), or severe cardiac disease (NYHA class III-IV heart failure).\n* History of alcohol consumption for ≥ 5 consecutive years.\n* Heavy smoker (Brinkman Index \\> 600).\n* Known allergy or intolerance to DLBS1033.\n* Autoimmune disease, malignancy, or acute and\u002For chronic inflammatory conditions other than diabetic polyneuropathy.\n* Participation in another interventional pharmacological clinical study within 30 days prior to screening.\n* Currently taking anti-inflammatory and\u002For antioxidant medications.","40 Years",{"count":387,"type":22},34,[25,389],"PHASE3","This study aims to evaluate whether oral DLBS1033 can improve clinical symptoms and biological markers of nerve damage in adults with diabetic polyneuropathy. The trial enrolls patients with type 2 diabetes who show clinical signs of peripheral nerve injury.\n\nParticipants will receive either DLBS1033 as adjuvant therapy or standard therapy alone for 28 days. The study will compare changes in neuropathy severity (Toronto Clinical Neuropathy Score), inflammatory biomarkers (TNF-α), neuroregeneration biomarkers (Nerve Growth Factor), and sensory nerve conduction parameters of the sural nerve between the two groups. Blood tests, clinical assessments, and nerve conduction studies will be performed at baseline and follow-up visits. Participants will also report any symptoms or adverse events throughout the study.",[392,393,31,394],"Diabetic Polyneuropathy","Peripheral Nervous System Diseases","Diabetes Mellitus",[396,397,398,204,399,400,401,402,403,404,405,406,407,408],"DLBS1033","lumbrokinase","diabetic polyneuropathy","Toronto Clinical Neuropathy Score","TNF-α","TNF-alpha","Nerve Growth Factor","sural nerve","nerve conduction study","NCS","EMG","ENMG","Electromyography","2026-03-13",{"date":411,"type":41},"2026-03-16",{"date":413,"type":22},"2026-03-01",{"date":415,"type":22},"2026-06-30",{"name":417,"class":48},"Universitas Sebelas Maret",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":348},"100322697","a-causative-role-for-amylin-in-diabetic-peripheral-neuropathy-100322697","NCT03481283","A Causative Role for Amylin in Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Subject has been diagnosed with Type-2 Diabetes.\n* Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.\n\nExclusion Criteria:\n\n* Subject has not been diagnosed with Type-2 Diabetes.\n* Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.",{"count":425,"type":22},40,"Three pieces of information lead to the basis for this study:\n\n1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy.\n2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes.\n3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin.\n\nThe purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.",[428,31],"Type2 Diabetes",[430],"Amylin","2026-01-28",{"date":433,"type":41},"2026-01-30",{"date":435,"type":41},"2018-02-05",{"date":437,"type":22},"2029-01",{"name":439,"class":48},"Zabeen Mahuwala, MD",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":446,"minAge":447,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":458,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":49},"100620786","exploring-the-effects-of-hand-and-foot-exercise-intervention-in-older-adults-with-gynecological-cancer-receiving-chemotherapy-improvement-of-peripheral-neuropathy-and-quality-of-life-100620786","NCT07362147","Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life","Inclusion Criteria:\n\nIndividuals aged 65 or older diagnosed with gynecological cancer (stage II to IV) by a physician, without skin or nail lesions.\n\nIndividuals who have received at least one course of chemotherapy within the past year and have peripheral neuropathy, with chemotherapy drugs including paclitaxel (Paclitaxel or Docetaxel) or platinum-based drugs (Cisplatin or Carboplatin), and may receive combined targeted or immunotherapy.\n\nIndividuals who are conscious and able to communicate in Mandarin, Taiwanese, or written language.\n\nExclusion Criteria:\n\nSkin or nail lesions. Edema of 3+ or more in the extremities. History of diagnosis of diabetes, neuropathy, peripheral arterial ischemia, or multiple organ failure.\n\nDistal bone or skin metastases. Patients who have interrupted chemotherapy. Patients who have participated in similar studies.","FEMALE","65 Years",{"count":449,"type":22},74,[60],"Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients. Peripheral neuropathy, a side effect of this treatment, presents with symptoms such as numbness, tingling, decreased skin and reflex sensation, and impaired function in the hands and feet, thus affecting quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel and platinum-based drugs, resulting from the cumulative toxicity of specific drug doses. While numerous international studies have confirmed the preventative effects of hand and foot movement interventions, there is a lack of relevant literature in China. Therefore, this study aims to explore the effects of hand and foot movement interventions on elderly gynecological cancer patients undergoing chemotherapy.",[31,453,454,455,456,457],"Cervical Cancer","Endometrial Cancer","Ovarian Cancer","Vaginal Cancers","Fallopian Tube Cancers",[459],"hand and foot exercises, chemotherapy, gynecological cancer, peripheral neuropathy, quality of life","2026-01-21",{"date":462,"type":41},"2026-01-23",{"date":464,"type":22},"2026-01-01",{"date":466,"type":22},"2027-11-30",{"name":468,"class":469},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":492},"100527733","a-prospective-natural-history-and-outcome-measure-discovery-study-of-charcot-marie-tooth-disease-type-4j-100527733","NCT06151600","A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J","CMT4J","Inclusion Criteria:\n\n1. Male or female, all ages\n2. A molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating 1) bi-allelic pathogenic and\u002For likely pathogenic variants (by ACMG criteria) in the FIG4 gene, or 2) bi-allelic variants with one pathogenic and\u002For likely pathogenic variant in trans with a variant of uncertain significance if laboratory evidence and expert consensus exits in support of loss of FIG4 function exists.\n3. Informed consent from patients 18 years or older who are able to provide consent and from caregivers; parent(s)\u002Fguardian(s) providing consent for subjects younger than 18 years at Screening and patients older than 18 years unable to provide informed consent\n4. Informed assent of patients younger than 18 years at Screening who are able to provide assent\n5. Able and willing to comply with the study protocol, including travel to Study Center, procedures, measurements and visits\n\nExclusion Criteria:\n\n1. Any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype\n2. Current participation in an interventional or therapeutic study\n3. Receiving an investigational drug within 90 days of the Baseline Visit\n4. Prior or current treatment with gene or stem cell therapy\n5. Any other diseases which may significantly interfere with the assessment of CMT4J\n6. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion or could interfere with the subject participating in or completing the study",{"count":478,"type":22},20,"This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.",[31,481,482],"Neuro-Degenerative Disease","Neuromuscular Diseases",{"date":484,"type":41},"2026-01-22",{"date":486,"type":41},"2024-07-29",{"date":488,"type":22},"2032-03-01",{"name":490,"class":491},"Elpida Therapeutics SPC","INDUSTRY",3,{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":499,"enrollmentInfo":500,"targetDuration":4,"studyType":23,"phases":502,"briefSummary":503,"conditions":504,"keywords":507,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":49},"100432286","intermittent-dosing-of-dorsal-root-ganglion-stimulation-as-an-alternate-paradigm-to-continuous-low-frequency-therapy-100432286","NCT04909138","Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy","Inclusion Criteria:\n\n* Age between 18 and 99\n* 1-year or more use of continuous DRG therapy as delivered a permanently implanted Abbott PROCLAIM XR Dorsal Root Ganglion Neurostimulator System for chronic back and\u002For leg pain\n* Endorse at least 50% pain relief in the targeted area over the last year\n* Must have been seen for routine follow-up within last 4 months\n* Must have been reprogrammed in standard fashion at least once prior to randomization\n* Willing and able to complete protocol requirements, including:\n\n  * Complete health questionnaires and pain scales as specified in the protocol\n  * Sign the study-specific informed consent form\n  * Complete follow-ups at the designated time periods\n\nExclusion Criteria:\n\n* Significant lead migration, as determined by clinician\n* Other concurrent neuromodulation system in place\n* Corticosteroid injection in previous 30 days prior to enrollment\n* Intermittent dosing and\u002For failure within last 6m\n* Changing or unstable pain medications within 30 days","90 Years",{"count":501,"type":22},30,[60],"This study seeks to evaluate the use of intermittent dosing as an alternative paradigm for patients with DRG stimulation in place for at least 1 year and minimum 50% pain relief in the targeted area.\n\nPatients will be prospectively randomized to one of two stimulation paradigms both of which involve intermittent dosing at 30 seconds ON and 90 seconds OFF. Group 1 will have their frequency set at 20 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation). Group 2 will have their frequency set at 5 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation) This study will be performed in a crossover fashion, meaning patients will be changed to the alternate dosing regimen at the 13-week time period.\n\nPatients will be seen and evaluated prior to randomization and reprogramming, and thereafter evaluated at 4, 8, and 12-weeks. At the 12-week time period, patients will begin a 1-week washout period of continuous stimulation. At the 13-week time period, patients will be evaluated, crossed over to the other study arm and thereafter evaluated at 17, 21, and 25-weeks.",[505,506,31],"CRPS (Complex Regional Pain Syndromes)","Radiculopathy",[108,508],"Dorsal Root Ganglion Stimulation","2026-01-18",{"date":460,"type":41},{"date":512,"type":41},"2022-10-15",{"date":514,"type":22},"2027-06",{"name":516,"class":48},"Rush University Medical Center",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":299,"sex":18,"minAge":19,"maxAge":499,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":49},"100525863","reliability-of-force-measurement-within-the-carbon-fiber-orthosis-proximal-cuff-100525863","NCT06127264","Reliability of Force Measurement Within the Carbon Fiber Orthosis Proximal Cuff","CuffForce","Group 1 - Able Bodied Participants\n\nInclusion Criteria\n\n* Between the ages of 18 and 65\n* Healthy without current complaint of lower extremity pain, spine pain, open wounds or active infections, or medical or neuromusculoskeletal disorders that have limited their participation in work or exercise in the last 6 months\n* Able to hop without pain\n* Able to perform a full squat without pain\n* Ability to read and write in English and provide written informed consent\n* Ability to fit in a generic sized CDO\n\nExclusion Criteria\n\n* Diagnosed with a moderate or severe brain injury\n* Lower extremity injury resulting in surgery or limiting function for greater than 6 weeks\n* Injuries that would limit performance in this study\n* Diagnosed with a physical or psychological condition that would preclude functional testing (e.g. cardiac condition, clotting disorder, pulmonary condition)\n* Visual or hearing impairments that limit walking ability or limit the ability to comply with instructions given during testing\n* Require use of an assistive device\n* Unhealed wounds (cuts\u002Fabrasions) that would prevent AFO use\n* BMI \\> 40\n* Pregnancy\n\nGroup 2 - AFO Users without Peripheral Neuropathy\n\nInclusion Criteria:\n\n* Between the ages of 18 and 90\n* Use an AFO(s) for daily activities\n* The AFO(s) proximal cuff is compatible with loadpad sensors\n* Have used their AFO(s) for a minimum of 2 weeks\n* Ability to walk 50 feet without use of an assistive device (e.g. cane, crutch, etc.)\n* Ability to read and write in English and provide written informed consent\n\nExclusion Criteria\n\n* Diagnosis or indication of peripheral neuropathy determined using Semmes Weinstein Filaments\n* Medical or psychological condition that would preclude functional testing (ex. Moderate or severe brain injury, stroke, heart disease)\n* Requirement of a knee stabilizing device (e.g. KAFO, KO) to preform daily activities\n* Visual or hearing impairments that limit walking ability or limit the ability to comply with instructions given during testing\n* BMI \\> 40\n* Pregnancy\n\nGroup 3 - AFO Users with Peripheral Neuropathy\n\nInclusion Criteria:\n\n* Between the ages of 18 and 90\n* Use an AFO(s) for daily activities\n* The AFO(s) proximal cuff is compatible with loadpad sensors\n* Have used their AFO(s) for a minimum of 2 weeks\n* Ability to walk 50 feet without use of an assistive device (e.g. cane, crutch, etc.)\n* Diagnosis or indication of peripheral neuropathy determined using Semmes Weinstein Filaments\n* Ability to read and write in English and provide written informed consent\n\nExclusion Criteria\n\n* Medical or psychological condition that would preclude functional testing (ex. Moderate or severe brain injury, stroke, heart disease)\n* Requirement of a knee stabilizing device (e.g. KAFO, KO) to preform daily activities\n* Visual or hearing impairments that limit walking ability or limit the ability to comply with instructions given during testing\n* BMI \\> 40\n* Pregnancy",{"count":332,"type":22},[60],"The primary purpose of this research study is to determine if forces within carbon fiber custom dynamic orthoses (CDOs) can be reliability assessed using Loadpad and Loadsol force measuring sensors (Novel GMBH, St. Paul, MN). An improved understanding of the forces acting within orthoses may help to guide future orthosis related research studies, provision methods, and patient education.\n\nStudy participants will consist of three groups; 1) healthy, able-bodied adult participants using generic sized CDOs, which consist of a proximal cuff that wraps around the leg just below the knee, a posterior carbon fiber strut that runs the length of the leg and bends to store and return energy, and a semi-rigid footplate that acts as a lever arm to bend the posterior strut, 2) individuals without peripheral neuropathy who use AFO(s) regularly, and 3) individuals with peripheral neuropathy who use AFO(s) regularly. .\n\nGroup 1 participants will be asked to fasten the proximal cuff to a self-selected cuff tightness 'SSCT', as well as three different predefined force levels; 'Loose' where the proximal cuff is loosely fastened around the participants leg, 'Moderate' where the proximal cuff is fastened with moderate tightness, and 'Tight' where the proximal cuff is tightly fastened around the participants leg. Testing in the predetermined force levels (Loose, Moderate, Tight) will occur in a randomized order. Group 2 and Group 3 participants will be asked to fasten their AFO(s) to a self-selected 'SSCT' tightness.\n\nFor all groups, forces acting on the leg, within the proximal cuff, will be measured using wireless Loadpad sensors and forces acting on the foot will be measured using wireless Loadsol insoles. Testing will include collection of force data as participants sit quietly, stand quietly, and walk and completion of questionnaires.",[528,529,31],"Healthy","Ankle Foot Orthosis (AFO)",[531,532,533],"Ankle Foot Orthosis","Carbon Fiber Orthosis","Plantar Force","2025-12-29",{"date":536,"type":41},"2025-12-31",{"date":538,"type":41},"2024-03-01",{"date":540,"type":22},"2026-12-31",{"name":542,"class":48},"University of Iowa",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":552,"conditions":553,"keywords":568,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":49},"100616152","generative-ai-impact-on-rheumatoid-arthritis-complications-diagnosis-100616152","NCT07301892","Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis","Impact of Generative Artificial Intelligence on Diagnosing Rheumatoid Arthritis Complications","Inclusion Criteria:\n\n* Patients with an initial diagnosis of rheumatoid arthritis (RA).\n* All real-world RA inpatients admitted to our department.\n* Admission occurring within the real-world data study period.\n\nExclusion Criteria:\n\n* Patients subsequently confirmed not to have RA during the study.",{"count":551,"type":22},100,"Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.",[554,555,556,557,558,559,560,561,562,563,564,565,31,566,567],"Rheumatoid Arthritis (RA","Osteoporosis","Osteoarthritis","Interstitial Lung Disease","Thyroid Diseases","Cardiovascular Diseases","Pulmonary Complications","Sjogren's Syndrome","Liver Disorders","Renal Lesions","Vasculitis","Amyloidosis","Thrombosis","RA Complications",[569,570,571,572],"Rheumatoid Arthritis","generative AI","large language model","Rheumatoid arthritis complications","2025-12-22",{"date":575,"type":41},"2025-12-24",{"date":577,"type":41},"2025-10-01",{"date":125,"type":22},{"name":580,"class":48},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":23,"phases":591,"briefSummary":592,"conditions":593,"keywords":597,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":49},"100616097","dod-atms-for-posttraumatic-peripheral-neuropathic-pain-100616097","NCT07301177","DoD AtMS for Posttraumatic Peripheral Neuropathic Pain","AtMS for Alleviating Posttraumatic Peripheral Neuropathic Pain (PTP-NP)","PTP-NP","Inclusion Criteria:\n\n* Veterans (men or women) of any race or ethnicity who are at least 18 years of age\n* Chronic peripheral neuropathic pain present for more than 4 months after a traumatic or surgical event per medical history\n* Have an average daily Numerical Pain Rating Scale (NPRS) score \\> 3\n* At least one negative or positive sensory sign or symptom confined to innervation territory of the lesioned nervous structure\n* Prior diagnostic tests confirming lesion or disease explaining neuropathic\n\nExclusion Criteria:\n\n* Pregnancy\n* Subjects with central neuropathic pain (ex: due to diabetic peripheral neuropathy, HIV, chemo\u002Fanti-viral therapy, carpal tunnel syndrome, post-traumatic pain classified as central rather than peripheral)\n* Subjects with pain due to Complex Regional Pain Syndrome\n* Phantom limb pain after amputation (stump pain and phantom sensation are allowed)\n* Subjects with skin conditions in the affected dermatome\n* Subjects with other pain such as lumbar or cervical radiculopathy that may confound assessment\n* Any subject considered at risk of suicide\n* Use of prohibited medications in the absence of appropriate washout periods\n* Participation in any other clinical trial within the 30 days prior to screening and\u002For during participation in this study\n* Heart pacemaker\n* Subjects with a current diagnosis of DSM-IV-TR Axis I disorder (GAD \\& MDD are allowed if clinically stable)\n* Subjects with pending lawsuits related to injury\n* Subjects who have previously received either transcranial or transcutaneous magnetic stimulation therapy in the past",{"count":590,"type":22},180,[60],"The goal of this clinical trial is to learn if adaptative transcutaneous magnetic stimulation (AtMS) works to reduce pain caused by post-traumatic peripheral neuropathic pain (PTP-NP) within Veterans and\u002For active duty military personnel. It will also learn about the safety of AtMS. The main questions it aims to answer are:\n\n1. What are the effects of adaptative tMS (AtMS) in alleviating patients' PTP-NP compared to fixed tMS (FtMS) and Sham-tMS?\n2. What are the effects of AtMS in improving functions in patients suffering from PTP-NP compared to FtMS and Sham-tMS?\n3. What are the effects of AtMS in improving mood in patients suffering from PTP NP compared FtMS and Sham-tMS?\n\nResearchers will compare AtMS, FtMS and Sham-tMS to see if AtMS is the best form of tMS in treating PTP-NP.\n\nParticipants will undergo the following:\n\n1. Receive a total of 8 AtMS, FtMS, or Sham-tMS treatments over 16 weeks.\n2. Visit the clinic a total of 12 times for assessments, check ups, and treatments.\n3. Keep a daily diary of their PTP-NP intensity, sleep interference, and pain medications used.",[594,31,595,596],"Posttraumatic Peripheral Neuropathic Pain","Peripheral Neuropathy Due to Surgical Trauma","Peripheral Neuropathy Due to Physical Trauma",[598,599,600,204,601,602],"adaptative transcutaneous magnetic stimulation (AtMS)","fixed transcutaneous magnetic stimulation (ftMS)","transcutaneous magnetic stimulation (tMS)","neuropathy","pain",{"date":575,"type":41},{"date":605,"type":41},"2025-04-30",{"date":607,"type":22},"2029-03",{"name":609,"class":48},"Veterans Medical Research Foundation",{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":23,"phases":619,"briefSummary":620,"conditions":621,"keywords":622,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":628,"leadSponsor":630,"locationsCount":4},"100611125","randomized-sham-controlled-investigation-of-the-leia-sensory-prosthesis-in-individuals-with-peripheral-neuropathy-100611125","NCT07236515","Randomized, Sham-Controlled Investigation of the Leia Sensory Prosthesis in Individuals With Peripheral Neuropathy","Randomized, Sham-Controlled, Multicenter Investigation of the Leia Sensory Prosthesis on Gait and Balance in Peripheral Neuropathy.","MYN-L001-001","Inclusion Criteria:\n\n* Signed informed consent prior to any study procedure.\n\n  * Adults ≥18 years.\n  * Clinical diagnosis of peripheral neuropathy.\n  * Willingness and ability to attend weekly sessions, perform home use, and return for follow-up.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years at the time of consent.\n* Active foot ulcer, infection, or severe dermatological condition at electrode contact sites.\n* Cognitive impairment that precludes informed consent or device use.\n* Implanted electrical devices or pacemakers.\n* Pregnancy\n* Usage of other medical devices for the relief of neuropathic symptoms during the trials.",{"count":104,"type":22},[60],"This study will evaluate a wearable device intended to support balance and gait in adults with peripheral neuropathy. Participants will use the device for a defined period, and outcomes related to safety, usability, and functional performance will be assessed.",[31],[68,623],"Sensory Prosthesis","2025-11-22",{"date":626,"type":41},"2025-11-28",{"date":464,"type":22},{"date":629,"type":22},"2028-08-01",{"name":631,"class":491},"MYNERVA AG",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":644,"conditions":645,"keywords":647,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":348},"100594865","phase-4-fenofibrate-role-in-the-prophylaxis-from-peripheral-neuropathy-induced-by-bortezomib-lenalidomide-and-dexamethasone-vrd-protocol-in-the-treatment-of-patients-with-multiple-myeloma-mm-100594865","NCT07025005","Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)","Clinical Study to Evaluate the Possible Role of Fenofibrate in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone Protocol in the Treatment of Patients With Multiple Myeloma","VRd MM Fibrate","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Newly diagnosed MM patients according to the revised International Myeloma Working Group Diagnostic Criteria for the diagnosis of Multiple Myeloma (IMWG).\n* Patients being treated by bortezomib-based VRd chemotherapy regimen.\n* Patients with performance status \\\u003C2 according to Eastern Cooperative Oncology Group (ECOG) score.\n* Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL and hemoglobin level ≥ 10 g\u002Fdl).\n* Patients with adequate liver function (serum bilirubin \\\u003C 1.2 mg\u002Fdl) and adequate renal function (serum creatinine \\\u003C 1.5 mg\u002Fd).\n\nExclusion Criteria:\n\n* Patients with prior exposure to neurotoxic agents (Cis-platin, vincristine, taxanes, foscarnet, INH, etc..) in the last 6 months.\n* Concomitant use of antioxidant vitamins (vitamin A, C, E), anticonvulsants, tricyclic antidepressants, other medications used for neuropathic pain (gabapentin, lamotrigine, carbamazepine).\n* Preexisting peripheral neuropathy resulting from other causes such as diabetes and brain disorders, hypothyroidism, autoimmune diseases, hepatitis C.\n* Patients with inflammatory diseases (ulcerative colitis, rheumatoid arthritis).\n* Patients with conditions associated with oxidative stress (smoking, tuberculosis, comorbid obesity).\n* Patients with active liver disease (cirrhosis, fatty liver, hepatitis C, etc..).\n* Patients with myopathy.\n* Patients with other malignancies.\n* Patients with renal impairment, including those with end-stage renal disease and those receiving dialysis.\n* Patients with Gallbladder disease and gallstones.\n* Pregnant and breast-feeding women.\n* Patients with Known allergy to the fenofibrates.\n* Concurrent use of statin, colchicine, Ciprofibrate, idelalisib, enzyme inducers (phenytoin, phenobarbitone, carbamazepine,…), enzyme inhibitors (ketoconazole, clarithromycin,…), drugs with high plasma protein binding capacity (Sulfonamides, valproate, oral hypoglycemic, warfarin,…) to avoid potential pharmacodynamics and pharmacokinetic drug interactions.",{"count":641,"type":22},44,[643],"PHASE4","This study aims at evaluating the possible beneficial role of Fenofibrate in attenuating the peripheral neuropathy associated with bortezomib (velcade), lenalidomide (revlimid), and dexamethasone (VRd) regimen in newly diagnosed multiple myeloma patients.The study aims to asses VRd protocol induced peripheral neuropathy through:\n\n1. The implication of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 5, 2017) and The use of Neurotoxicity-12 items questionnaire score (Ntx-12) from the validated Functional Assessment of Cancer Therapy\u002FGynecologic Oncology Group \"FACT\u002FGOG-Ntx-12 for grading of neuropathy at baseline and by the end of every two VRd cycles.\n2. The assessment of biological markers:\n\nBrain -derived neurotrophic factor (BDNF) and Neuro-filament light chain (NfL). through comparing two groups: Group one: (Control group; n=22): which will receive 6 cycles of VRd regimen (each cycle will be given every 28 days).\n\nGroup two: (Fenofibrate group; n=22): which will receive the same regimen plus Fenofibrate 160 mg once daily.",[31,646],"Multiple Myeloma, Neoplasms",[204,648,649,650,651,652],"multiple myeloma","bortezomib induced peripheral neuropathy (BIPN)","Fenofibrate","VRd protocol","lenalidomide","2025-11-01",{"date":655,"type":41},"2025-11-04",{"date":657,"type":41},"2025-08-30",{"date":659,"type":22},"2026-09-30",{"name":661,"class":48},"Tanta University",{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":299,"sex":18,"minAge":19,"maxAge":669,"enrollmentInfo":670,"targetDuration":672,"studyType":105,"phases":4,"briefSummary":673,"conditions":674,"keywords":679,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":49},"100563396","our-study-aims-to-determine-if-nerve-alterations-in-acute-gbs-and-cidp-detectable-by-ultrasound-match-electrodiagnostic-findings-and-if-this-method-aids-early-diagnosis-predict-their-outcomes-and-differentiate-between-axonal-and-demyelinating-subtypes-100563396","NCT06615622","Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes.","A Comparative Study of Peripheral Nerve Ultrasound Findings in Immune Mediated Peripheral Nerve Disorders; a Hospital-based Study","Inclusion Criteria:\n\n1. Diagnosis of patient group:\n\n   * GBS Patients: Diagnosed according to the criteria of the National Institute of Neurological Disorders and Stroke (NINDS) and the Brighton Collaboration (2011).\n   * CIDP Patients: Diagnosed according to the criteria of the European Federation of Neurological Societies\u002FPeripheral Nerve Society (EFNS\u002FPNS).\n2. Age: Participants aged 18 to 75 years.\n3. Onset:\n\n   * GBS Patients: Recent onset of GBS within the first 2 weeks of symptom onset.\n   * CIDP Patients: Either relapsing or progressive course consistent with CIDP diagnosis.\n4. Gender: Both male and female participants are eligible.\n5. Participation: Willingness to participate in the study, including undergoing disease-related examinations and assessments.\n6. Consent: Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n1. Patients unable or unwilling to provide informed consent.\n2. Patients with metabolic disorders or malignancies.\n3. Patients with other causes of peripheral neuropathy.\n4. Patients with other causes of acute flaccid paralysis.","75 Years",{"count":671,"type":22},90,"6 Months","Neuromuscular ultrasound (NMUS) is emerging as a valuable non-invasive diagnostic tool. In GBS, NMUS can detect proximal nerve enlargement early, before neurophysiological changes. Persistent nerve enlargement can be observed up to 15 years, though its correlation with disability varies. Research is needed to clarify NMUS findings in GBS and CIDP over time. Early detection of nerve root enlargement via NMUS could facilitate earlier diagnosis and intervention, improving patient outcomes and understanding of these conditions\\' pathophysiology.\n\nThis study aims to determine if nerve alterations in acute GBS and CIDP detectable by ultrasound match electrodiagnostic findings and if this method aids early diagnosis. The investigators will perform serial nerve ultrasounds and NCS to investigate nerve morphology, predict outcomes, and differentiate between axonal and demyelinating subtypes.",[675,676,677,678,31],"Guillain Barré Syndrome","Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Peripheral Nerve Disorder","Peripheral Nerves US",[680,681,682,683],"Peripheral nerve ultrasound","immune mediated nerve disorders","Guillain-Barré syndrome","Chronic inflammatory demyelinating polyradiculoneuropathy",{"date":685,"type":41},"2025-10-03",{"date":687,"type":41},"2024-09-01",{"date":689,"type":22},"2028-03-30",{"name":691,"class":48},"Assiut University",{"id":693,"slug":694,"hasResults":12,"nctId":695,"briefTitle":696,"officialTitle":697,"acronym":698,"eligibilityCriteria":699,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":499,"enrollmentInfo":700,"targetDuration":701,"studyType":105,"phases":4,"briefSummary":702,"conditions":703,"keywords":705,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":709,"lastUpdatePostDateStruct":710,"startDateStruct":712,"completionDateStruct":714,"leadSponsor":716,"locationsCount":4},"100606223","the-pressure-relieving-capacity-of-siliconepads-compared-to-felted-foam-to-relieve-caput-metatarsal-2-in-a-population-with-diabetes-100606223","NCT07172763","The Pressure Relieving Capacity of Siliconepads Compared to Felted Foam to Relieve Caput Metatarsal 2 in a Population With Diabetes","The Pressure Relieving Capacity of Siliconepads Compared to Felted Foam to Relieve Caput Metatarsal 2 in a Population With Diabetes at High Risk of Foot Ulcerations","Siliconepads","Inclusion Criteria:\n\n* Diabetes, Peripheral neuropathy, able to walk 5 minutes, able to sign informed consent\n\nExclusion Criteria:\n\n* No diabetes, No neuropathy, not able to walk without walking aid, not able to sign informed consent",{"count":104,"type":22},"1 Week","To evaluate the clinical effectiveness of siliconepads and if they could be an alternative to felted foam used in offloading high risk pressure areas in the plantar forefoot region using plantar pressure measurements.\n\nAlso user experience will be evaluated which is an important criterion in the use of this new type of offloading. Comfort, convenience and functionality of both felted foam and siliconepads will be tested to evaluate if siliconepads are more appropriate then felted foam.",[704,31],"Diabete Mellitus",[143,706,698,707,708],"Sensory peripheral neuropathy","Felted foam","Plantar pressure measurement","2025-09-16",{"date":711,"type":41},"2025-09-22",{"date":713,"type":22},"2025-10-08",{"date":715,"type":22},"2028-10-30",{"name":717,"class":48},"University Hospital, Ghent"]